Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol

Detalhes bibliográficos
Autor(a) principal: Dulley,Frederico Luiz
Data de Publicação: 2005
Outros Autores: Saboya,Rosaura, Hungria,Vânia Tietsche de Moraes, Bueno,Nadjanara Dorna, Mello,Fernando Gomes de, Frota,Maria Tereza, Chiattone,Carlos Sergio, Barros,José Carlos, Mori,Nair Sumie, Sturaro,Daniel, Macedo,Maria Cristina Martins de Almeida, Silva,Roberto Luiz da, Melo,Leila Maria Magalhães Pessoa de, Souza,Cármino Antonio
Tipo de documento: Artigo
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600003
Resumo: CONTEXT AND OBJECTIVE: Liposomal daunorubicin has been used to treat hematological malignancies, including multiple myeloma (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone ("DD Protocol"). DESIGN AND SETTING: Prospective study at Sírio-Libanês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. METHODS: Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m²/day) on three consecutive days per month, with oral dexamethasone (10 mg every six hours) on four consecutive days three times a month. RESULTS: The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hematological toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm³; none had thrombocytopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexia (15%) and no vomiting. CONCLUSIONS: This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marrow transplantation.
id APM-1_5c3bbf0e35add9fe37922b903023c365
oai_identifier_str oai:scielo:S1516-31802005000600003
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD ProtocolMultiple myelomaDaunorubicinDexamethasoneDrug therapyDrug toxicityCONTEXT AND OBJECTIVE: Liposomal daunorubicin has been used to treat hematological malignancies, including multiple myeloma (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone ("DD Protocol"). DESIGN AND SETTING: Prospective study at Sírio-Libanês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. METHODS: Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m²/day) on three consecutive days per month, with oral dexamethasone (10 mg every six hours) on four consecutive days three times a month. RESULTS: The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hematological toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm³; none had thrombocytopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexia (15%) and no vomiting. CONCLUSIONS: This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marrow transplantation.Associação Paulista de Medicina - APM2005-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600003Sao Paulo Medical Journal v.123 n.6 2005reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/S1516-31802005000600003info:eu-repo/semantics/openAccessDulley,Frederico LuizSaboya,RosauraHungria,Vânia Tietsche de MoraesBueno,Nadjanara DornaMello,Fernando Gomes deFrota,Maria TerezaChiattone,Carlos SergioBarros,José CarlosMori,Nair SumieSturaro,DanielMacedo,Maria Cristina Martins de AlmeidaSilva,Roberto Luiz daMelo,Leila Maria Magalhães Pessoa deSouza,Cármino Antonioeng2006-01-20T00:00:00Zoai:scielo:S1516-31802005000600003Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2006-01-20T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
title Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
spellingShingle Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
Dulley,Frederico Luiz
Multiple myeloma
Daunorubicin
Dexamethasone
Drug therapy
Drug toxicity
title_short Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
title_full Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
title_fullStr Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
title_full_unstemmed Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
title_sort Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
author Dulley,Frederico Luiz
author_facet Dulley,Frederico Luiz
Saboya,Rosaura
Hungria,Vânia Tietsche de Moraes
Bueno,Nadjanara Dorna
Mello,Fernando Gomes de
Frota,Maria Tereza
Chiattone,Carlos Sergio
Barros,José Carlos
Mori,Nair Sumie
Sturaro,Daniel
Macedo,Maria Cristina Martins de Almeida
Silva,Roberto Luiz da
Melo,Leila Maria Magalhães Pessoa de
Souza,Cármino Antonio
author_role author
author2 Saboya,Rosaura
Hungria,Vânia Tietsche de Moraes
Bueno,Nadjanara Dorna
Mello,Fernando Gomes de
Frota,Maria Tereza
Chiattone,Carlos Sergio
Barros,José Carlos
Mori,Nair Sumie
Sturaro,Daniel
Macedo,Maria Cristina Martins de Almeida
Silva,Roberto Luiz da
Melo,Leila Maria Magalhães Pessoa de
Souza,Cármino Antonio
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Dulley,Frederico Luiz
Saboya,Rosaura
Hungria,Vânia Tietsche de Moraes
Bueno,Nadjanara Dorna
Mello,Fernando Gomes de
Frota,Maria Tereza
Chiattone,Carlos Sergio
Barros,José Carlos
Mori,Nair Sumie
Sturaro,Daniel
Macedo,Maria Cristina Martins de Almeida
Silva,Roberto Luiz da
Melo,Leila Maria Magalhães Pessoa de
Souza,Cármino Antonio
dc.subject.por.fl_str_mv Multiple myeloma
Daunorubicin
Dexamethasone
Drug therapy
Drug toxicity
topic Multiple myeloma
Daunorubicin
Dexamethasone
Drug therapy
Drug toxicity
description CONTEXT AND OBJECTIVE: Liposomal daunorubicin has been used to treat hematological malignancies, including multiple myeloma (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone ("DD Protocol"). DESIGN AND SETTING: Prospective study at Sírio-Libanês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. METHODS: Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m²/day) on three consecutive days per month, with oral dexamethasone (10 mg every six hours) on four consecutive days three times a month. RESULTS: The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hematological toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm³; none had thrombocytopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexia (15%) and no vomiting. CONCLUSIONS: This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marrow transplantation.
publishDate 2005
dc.date.none.fl_str_mv 2005-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600003
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600003
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-31802005000600003
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv Sao Paulo Medical Journal v.123 n.6 2005
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1754209261292879872